Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity by Teng YKO et al.
Newcastle University e-prints  
Date deposited:  4th January 2012 
Version of file:  Published 
Peer Review Status: Peer reviewed 
Citation for item: 
Teng YKO, Wheater G, Hogan VE, Stocks P, Levarht EWN, Huizinga TWJ, Toes REM, van Laar 
JM. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially 
affects autoreactive more than protective humoral immunity. Arthritis Research & 
Therapy 2012, 14(2), R57. 
Further information on publisher website: 
http://arthritis-research.com  
Publisher’s copyright statement: 
© 2012 Teng et al.; licensee BioMed Central Ltd.  
This is an open access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
The definitive version of this article is available at: 
http://dx.doi.org/10.1186/ar3770 
Always use the definitive version when citing.   
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
 A full bibliographic reference is made to the original source 
 A link is made to the metadata record in Newcastle E-prints 
 The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU.  Tel. 0191 222 6000 
RESEARCH ARTICLE Open Access
Induction of long-term B-cell depletion in
refractory rheumatoid arthritis patients
preferentially affects autoreactive more than
protective humoral immunity
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Abstract
Introduction: B-cell depletion has become a common treatment strategy in anti-TNF-refractory rheumatoid
arthritis (RA). Although the exact mechanism of how B-cell depletion leads to clinical amelioration in RA remains to
be elucidated, repetitive treatment with B-cell-depleting agents leading to long-term B-cell depletion has been
reported to be beneficial. The latter has led to the hypothesis that the beneficial effects of B-cell depletion might
act through their influence on pathogenic autoreactive plasma cells.
Methods: In this study, we investigated the effects of a fixed retreatment regimen with anti-CD20 mAbs on the
humoral (auto)immune system in a cohort of therapy-refractory RA patients.
Results: Fixed retreatment led to long-term B-cell depletion in peripheral blood, bone marrow and, to a lesser
extent, synovium. Also, pathologic autoantibody secretion (that is, anticitrullinated peptide antibodies (ACPAs)) was
more profoundly affected by long-term depletion than by physiological protective antibody secretion (that is,
against measles, mumps and rubella). This was further illustrated by a significantly shorter estimated life span of
ACPA-IgG secretion compared to total IgG secretion as well as protective antibody secretion.
Conclusion: By studying plasma cell function during an extensive 2-year period of B-cell depletion, autoantibody
secretion was significantly shorter-lived than physiologically protective antibody secretion. This suggests that the
longevity of autoreactive plasma cells is different from protective long-lived plasma cells and might indicate a
therapeutic window for therapies that target plasma cells.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease typically characterised by symmetrical polyarthritis,
joint destruction and an impaired quality of life. RA
patients are generally treated with disease-modifying
antirheumatic drugs (DMARDs) and, when treatment
fails, with biologicals, including inhibitors of TNFa
(anti-TNFa) [1]. Recommendations for the use of other
biologicals, notably for B-cell-depleting mAbs, propagate
their use to RA patients in whom treatment with TNF-
depleting monoclonal antibodies has failed [2]. Several
clinical studies have demonstrated the efficacy of B-cell
depletion in RA [3-5]. As the therapeutic effects of a
single treatment course are transient in the majority of
patients, repeat treatment with B-cell-depleting agents is
necessary to maintain efficacy [6-8]. The rationale for
depleting B cells in RA is based on the role of the
humoral immune system in the pathogenesis of RA. The
latter is supported by clinical studies showing that sero-
positive (for rheumatoid factor (RF) and anticitrullinated
protein antibodies (ACPAs)) RA patients, who have
more severe disease and a worse prognosis [9,10],
respond better to B-cell-depleting therapy. Thus far
whether the beneficial effects of B-cell depletion act
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through their influence on pathogenic autoreactive
plasma cells remains speculative [11-13]. It has been
shown that after one course of rituximab, serum con-
centrations of ACPA-immunoglobulin G (IgG) and RF-
IgM decrease specifically, in contrast to antibodies
against tetanus toxoid [3,14]. These observations can be
explained by the direct cytotoxic effects of rituximab on
CD20+ short-lived plasmablasts, in contrast to CD20-
long-lived plasma cells. Importantly, although serum
concentrations decreased, autoantibody secretion was
not abrogated completely, which is indicative of persist-
ing autoreactive plasma cells. As a consequence, target-
ing these long-lived autoreactive plasma cells has been a
recent focus of clinical research [15]. Induction of long-
lasting B-cell depletion is one possible way to target
plasma cells indirectly by inhibiting B-cell differentiation
and thus the production of long-lived plasma cells.
Therefore, in the present study, we investigated a
population of RA patients in whom B-cell depletion was
achieved for a period of at least 2 years (further referred
to as ‘long-term B-cell depletion’) and studied its effects
on the humoral (auto)immune system. This study was
part of an open-label feasibility study in which refractory
RA patients were treated with a regimen of fixed repeat
treatment with rituximab as a means to achieve persis-
tent B-cell depletion during the 2-year study period.
Our aim in this proof-of-principle study was to investi-
gate whether plasma cells, either autoreactive or protec-
tive, were directly or indirectly affected by long-term B-
cell depletion. To this end we analysed blood, bone mar-
row and synovium to examine the extent of B-cell
depletion and its effects on the secretion of RA-specific
autoantibodies as well as physiological protective anti-
body secretion.
Methods
Study design
The present study involved paired samples of blood,
bone marrow and synovium from 11 patients with
severe RA who were positive for IgM rheumatoid factor
(RF-IgM) and IgG autoantibodies against cyclic citrulli-
nated peptides (ACPA-IgG). These patients were
selected from among a cohort of 28 RA patients refrac-
tory to TNFa inhibitors who participated in a single-
centre, open-label, phase I/II trial to investigate the
safety, feasibility and efficacy of maintenance treatment
with rituximab as described previously [16]. Seventeen
patients were excluded from this study for the following
reasons: three patients were excluded because of incom-
plete sampling, five patients because of the absence of
RF-IgM and ACPA-IgG and nine patients dropped out
of the study before 24 months (four patients because of
infections, five patients for miscellaneous reasons: one
serious infusion reaction, one accident requiring surgery,
one inefficacy, one death and one lost to follow-up). The
study protocol was approved by the Ethics Committee
of the Leiden University Medical Center, and all patients
gave their written informed consent.
Study patients
The patients’ median age was 54 years (range: 33 to 64),
eight patients (73%) were female and the median disease
duration was 12.4 years (range: 1.3 to 32.3). Patients had
used a median of four DMARDs (range: two to six) and
one TNF-blocking agent (range: zero to three). (One
patient had a relative contraindication to TNF-blocking
agents due to a history of B-cell lymphoma.) The
patients’ current medications included methotrexate
(median dose of 15 mg/week (range: 2.5 to 25.0) in 11
patients) and oral prednisolone (median dose of 8.75
mg/day (range: 2.5 to 20.0) in 6 patients).
The median Disease Activity Score in 28 joints
(DAS28), as assessed by the four-variable DAS28 accord-
ing to the European League Against Rheumatism guide-
lines, was 6.15 (range: 3.01 to 7.67). The median
erythrocyte sedimentation rate (ESR) was 49 mm/first
hour (range: 5 to 134), and the median C-reactive pro-
tein (CRP) level was 24 mg/L (range: 2 to 110). The
median Health Assessment Questionnaire (HAQ) score
was 1.38 (range: 0.12 to 2.25), as assessed using the
HAQ to quantify patients’ functional disability. The
median Sharp/van der Heijde score, which is used to
assess joint damage based on X-rays of the hands and
feet, was 51 (range: 20 to 164).
Synovial tissue analysis
Arthroscopy of clinically affected knees and sampling of
synovial tissue specimens was performed in all patients.
Synovial tissue specimens were stored in formalin and
embedded in paraffin. Paraffin-embedded sections were
cut for staining, encoded and semiquantitatively scored
as previously described [16].
Flow cytometric analysis
Blood samples and bone marrow aspirates (anticoagu-
lated by using ethylenediaminetetraacetic acid) were
obtained as described previously [16]. According to a
stain-wash-no-lyse protocol, an estimated 500 × 103
cells were incubated with mouse anti-human mAbs, as
specified below, in PBS/1% BSA at room temperature
for 15 minutes. Next, fluorescence-activated cell sorting
(FACS) lysing solution (BD Biosciences, San Jose, CA,
USA) was used to lyse erythrocytes, after which cells
were analysed immediately with a FACSCalibur flow
cytometer (BD Biosciences). To allow quantification of
cell numbers in each sample, 104 Flow-Count Fluoro-
spheres (Beckman Coulter, Miami, FL, USA) were added
immediately before flow cytometric analysis. The
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frequencies within the lymphocyte population were cal-
culated using FlowJo software (Tree Star, Inc, Ashland,
OR, USA). The detection limits were 1 × 106 cells/L in
peripheral blood and 1% of lymphocytes in bone mar-
row. The following mAbs were used: anti-CD19-fluores-
cein isothiocyanate (H1B19), anti-CD19-phycoerythrin
(anti-CD-19-PE; H1B19), anti-CD19-PerCP-Cy5.5
(SJ25C1) and anti-CD3-APC (UCHT1) (all from BD
Biosciences).
Flow cytometric cell sorting
Bone marrow mononuclear cells (BMMCs; 30 × 106)
were stained for flow cytometric cell sorting with mouse
anti-human mAbs in PBS/1% BSA for 30 minutes at 4°C
in the dark. The following mAbs were used: anti-IgD-PE
(IAG-2), anti-CD38-PerCP-Cy5.5 (HIT-2) and anti-CD3-
APC (UCHT1). Thereafter BMMCs were thoroughly
washed and resuspended in PBS/1% BSA and immedi-
ately sorted into Iscove’s modified Dulbecco’s medium
(IMDM)/50% FCS by using a FACSAria flow cytometer
(BD Biosciences). Sorted cell populations were then
titrated into ELISPOT plates (BD Biosciences) as men-
tioned below.
Enzyme-linked immunosorbent spot assays
Ninety-six-well microtitre plates were coated with 100
μl/well goat anti-human poly-Ig (15 μg/ml) and PBS as
control. The plates were incubated overnight at 4°C.
They were then washed twice with PBS and blocked
with 200 μl/well culture medium (IMDM + 10% FCS +
200 mM L-glutamine + 100 μg/ml penicillin/streptavi-
din) for 2 hours at 37°C in a 5% CO2 atmosphere. FACS
cell populations were titrated into the ELISPOT plates
in duplicate wells, and the plates were then incubated at
37°C in a 5% CO2 atmosphere overnight. The following
day cells were discarded and washed from the plates
with PBS/0.05% Tween 20 and tap water. Spots were
visualised by detection with alkaline phosphatase-conju-
gated goat anti-human IgG, IgM or IgA, followed by
substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium (Sigma-Aldrich, St Louis, MO, USA) at
100 μl/well. Enzyme-linked immunosorbent spots (Eli-
spots) were analysed using a stereomicroscope (Biorea-
der 3000 Pro; BIO-SYS GmbH, Karben, Germany), and
the number of spots detected was plotted against the
titrated number of cells per well, resulting in a sigmoid-
shaped curve. The representative number of spots was
selected from the linear part of the curve, then the data
were presented as the mean frequency of IgG-, IgM-
and IgA-secreting cells/106 mononuclear cells.
Measurements of serum antibody concentrations
Serial serum samples taken from each patient were ana-
lysed for concentrations of total immunoglobulins,
autoantibodies and protective antibodies. Total serum
concentrations of IgG and IgM were measured by
immunoturbidimetry on the COBAS INTEGRA 400 700
800 (Roche Diagnostics, Indianapolis, IN, USA) accord-
ing to the manufacturer’s guidelines.
Serum concentrations of RF-IgM were measured using
a standardised ELISA as previously described [17].
Serum concentrations of ACPA-IgG, ACPA-IgM and
ACPA-IgA were measured using a commercially avail-
able ELISA (Immunoscan RA Mark 2; Euro-Diagnostica,
Arnhem, The Netherlands) according to the manufac-
turer’s instructions and as previously described [18].
Statistical analysis
Nonparametric Wilcoxon tests were used to compare
follow-up concentrations of total immunoglobulins,
autoantibodies and protective antibodies (measles,
mumps and rubella) at baseline versus 6 months and at
baseline versus 24 months. The lifetime of immunoglo-
bulin-secreting cell populations was estimated by extra-
polation of the measured serum concentrations during
the 2 years of B-cell depletion. For each separate (auto)
antibody, the consecutive median concentrations from 6
months to 24 months (thus excluding baseline values)
were used to produce a linear fit curve, from which the
lifetime was calculated (that is, the time point at which
the fit curve crossed the x-axis). P-values less than 0.05
were considered significant.
Results
Fixed retreatment with rituximab induces long-term B-cell
depletion in different tissue compartments of refractory
rheumatoid arthritis patients
RA patients were treated with rituximab every 6 months
in our prospective study, the clinical results of which
have been published elsewhere [8]. The B-cell-depleting
effects of this fixed retreatment protocol in peripheral
blood and bone marrow are shown in Figure 1. We
observed a significant reduction in absolute B-cell num-
bers in peripheral blood (Figure 1A). At baseline,
patients had a median number of 189 × 106 cells/L
(range: 87 to 353 × 106) CD3-CD19+ B cells. After each
rituximab course, B-cell numbers fell to undetectable
numbers as follows: In 10 of 11 patients at 3 months, B
cells ranged from 0 to 1 × 106 cells/L; in 8 of 11
patients at 9 months, B cells ranged from 0 to 1 × 106
cells/L; in 10 of 11 patients at 15 months, B cells ranged
from 0 to 1 × 106 cells/L; and in 10 of 11 patients at 21
months, B cells ranged from 0 to 4 × 106 cells/L. B-cell
numbers started to rise about 6 months after each ritux-
imab course, upon which patients were retreated with a
subsequent course. Circulating numbers of B cells were
persistently undetectable in 5 of 11 patients at 6 months
(range: 0 to 425 × 106 cells/L), in 6 of 11 patients at 12
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months (range: 0 to 59 × 106 cells/L), in 7 of 11 patients
at 18 months (range: 0 to 113 × 106 cells/L) and in 5 of
11 patients at 24 months (range: 0 to 79 × 106 cells/L)
(Figure 1A). Overall, five patients had persistently unde-
tectable B-cell numbers during the complete 2-year fol-
low-up. In bone marrow, CD3-CD19+ B cells were
effectively depleted from the baseline median 1% (range:
0% to 4%) of mononuclear cells to undetectable levels at
3 months and 21 months in all patients (Figure 1B).
Synovial tissue samples were collected from 9 of 11
patients at baseline and 3 months, which showed non-
significant reductions of semiquantative scores for
CD79a+ B cells from a baseline median score of 2
(range: 0 to 4) to a median score of 2 (range: 0 to 3) (P
= 0.41). Synovial tissue samples from six patients were
available at 21 months, with the median score being 1
(range: 0 to 2; P = 0.70 compared to baseline). Impor-
tantly, CD20+ cells were undetectable in all patients at 3
and 21 months. Nonsignificant changes were seen in
CD138+ plasma cells, with a median baseline score of 1
(range: 0 to 4) versus a median score of 1 at 3 months
(range: 0 to 3; P = 0.49) and 0.5 at 21 months (n = 6
patients) (range: 0 to 2; P = 0.17 compared to baseline).
Significant increases in serum B lymphocyte-activating
factor (BAFF) concentrations were observed after the
first rituximab treatment. The baseline median concen-
tration of 1,560 pg/ml (range: 940 to 2,361) increased to
a median concentration of 4,499 pg/ml (range: 2,520 to
9,693) at 6 months (P = 0.005). Also, after 24 months,
serum BAFF concentrations were significantly increased
up to 6,950 pg/ml (range: 3,339 to 13,040) compared to
6 months (P = 0.005) (Figure 1C).
Clinically, patients had highly active disease, with the
median DAS28 score being 6.15 (range: 3.01 to 7.67),
which improved gradually to a median DAS28 score of
2.79 (range: 1.47 to 4.67) at the end of the 2-year study
period (Figure 1D). A DAS28 score below 3.2 indicated
low disease activity, which was achieved in 9 of 11
patients at the end of the study. One patient had a
relapsing-remitting response to each rituximab treat-
ment, and one patient showed improvement of severe
disease (baseline DAS28 score 7.7) to moderate disease
Figure 1 Long-term B-cell depletion in peripheral blood and bone marrow in rheumatoid arthritis patients treated with a fixed
regimen of 6-monthly anti-CD20 monoclonal antibodies with a follow-up of 24 months. (A) Absolute numbers of CD3-CD19+ B cells
measured in peripheral blood every 3 months presented as Tukey box-and-whisker plots. (B) Percentages of CD3-CD19+ B cells in bone marrow
measured at baseline, 3 and 21 months presented as Tukey box-and-whisker plots. (C) Serum B lymphocyte-activating factor (BAFF)
concentrations before every rituximab course presented as Tukey box-and-whisker plots. (D) Disease Activity Score in 28 joints (DAS28) of the 11
individual patients (grey lines) and overall median DAS28 scores (black line) measured every 3 months. A DAS28 score below 3.2 (dotted line)
indicates low disease activity.
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activity (DAS28 score 4.7). Median levels of CRP and
ESR, used as indicators of inflammation, decreased from
24 mg/L (range: 2 to 110) to 4 mg/L (range: 2 to 31)
and from 49 mm/first hour (range: 5 to 134) to 19 mm/
first hour (range: 5 to 89), respectively.
IgM, IgG and IgA secretion is derived from different CD3-
CD38bright cell populations in bone marrow
Next, we aimed to identify by flow cytometry the cell
populations in bone marrow which were responsible for
IgG, IgA and IgM secretion. Therefore, we investigated
immunoglobulin secretion of cell populations sorted by
flow cytometry on the basis of CD38 and IgD expression
in conjunction with Elispot analysis (Figure 2A). The
results are expressed as spot-forming units (SFU)/106
cells. In the CD3-CD38brightIgD- cell population, we
detected predominantly IgG-secreting cells (mean ±
SEM: 107,067 ± 58,880 SFU/106 cells) and IgA-secreting
cells (mean ± SEM: 33,667 ± 10,364 SFU/106 cells). A
minority of CD3-CD38brightIgD- cells were IgM-secreting
cells (mean ± SEM: 3,733 ± 1,444 SFU/106 cells) (Figure
2B). In the CD3-CD38brightIgD+ cell population, only
IgM-secreting cells were detected (Figure 2B). With
respect to the overall population of immunoglobulin-
secreting cells, we observed significantly less SFUs in
the cell populations with lower CD38 expression. The
majority of immunoglobulin-secreting cells were found
in the CD38bright cell populations, with a minor fraction
of IgA-secreting cells in the CD382+ cell population
(Figure 2C). To further illustrate this finding, we
Figure 2 Immunoglobulin secretion from CD3-CD38bright cells in bone marrow. (A) Fresh bone marrow-derived mononuclear cells (BMMCs)
were stained with PerCP cyanin 5.5 dye for flow cytometric cell sorting (FL2H) according to immunoglobulin D (IgD) phycoerythrin and CD38
expression, resulting in four populations: CD38low cells, IgD+CD38high cells, IgD-CD382+ cells and IgD-CD38bright cells. These cell populations were
incubated on precoated ELISPOT plates as described in the Methods section. (B) Using the enzyme-linked immunosorbent spot assay, we
detected the number of spot-forming units (SFUs) and quantified them for the IgG, IgM and IgA isotypes. PBS = phosphate-buffered saline. Bars
represent means ± SEM of five experiments. (C) Calculated total number of SFUs for total immunoglobulin (total Ig) secretion. (D) 2 × 2 table
showing the sensitivity and specificity of the population of CD3-CD38bright cells to secrete immunoglobulins. The sensitivity was 92.9%, and the
specificity was 53.6%. FACS = fluorescence-activated cell sorting.
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calculated that the sensitivity for detecting immunoglo-
bulin secretion in CD3-CD38brightIgD- cells was 92.9%
(Figure 2D).
Taken together, these data confirm that, in bone mar-
row, IgG and IgA secretion, as compared to IgM secre-
tion, derive from different cell populations
distinguishable by CD38 and IgD expression, presum-
ably plasmablasts (CD3-CD38brightIgD+) and plasma cells
(CD3-CD38brightIgD-), based upon the immunoglobulin
isotypes secreted.
Immunoglobulin G autoantibody secretion is
preferentially affected during long-term B-cell depletion
in comparison to protective immunoglobulin G antibody
secretion
To evaluate the effects of long-term B-cell depletion on
plasma cell-derived immunoglobulin secretion, serum
concentrations of protective antibodies of the IgG iso-
type (that is, mumps, measles and rubella) were com-
pared to serum concentrations of ACPA-IgG and to
total IgG. As a control for plasmablast-derived immuno-
globulin secretion, serum concentrations of total IgM,
ACPA-IgM and RF-IgM, respectively, were measured.
As shown in Table 1, serum concentrations of total IgG
and IgM, as well as those of ACPA-IgG, ACPA-IgM and
RF-IgM, decreased significantly after 6 months (effect of
first treatment course) and also after 24 months (effect
of the fixed retreatment regimen). Interestingly, total
IgA and ACPA-IgA showed similar significantly decreas-
ing trends after long-term B-cell depletion. These reduc-
tions were in contrast to the constant course of serum
concentrations of measles-IgG, mumps-IgG and rubella-
IgG over the entire 2 years of follow-up (Table 1).
To further unravel whether long-term B-cell depletion
specifically reduced autoantibody secretion, the percen-
tage change from baseline of total serum IgG was com-
pared to the different IgG specificities (Figure 3). We
found that the relative reduction from baseline of total
IgG (median 74%, range: 52% to 107%) was significantly
larger than the reductions of measles-IgG (median
104%, range: 77% to 120%; P = 0.004), mumps-IgG
(median 107%, range: 78% to 121%; P = 0.003) and
rubella-IgG (median 96%, range: 54% to 138%; P =
0.03). In addition, the relative reduction of ACPA-IgG
(median 48%, range: 16% to 85%) was significantly larger
than that of total IgG (median 74%, range: 52% to 107%)
(P = 0.01) (Figure 3A). Illustratively, when assuming a
B-cell-depleted state would be maintained, we estimated
by means of extrapolation that the survival of ACPA-
IgG-secreting cells was 9.1 years (linear fit curve, Spear-
man’s r = 0.89) compared to an estimated lifetime of
38.3 years (Spearman’s r = 0.89) for the total IgG-
secreting cell population and infinite (∞) lifetime for
measles-IgG, mumps-IgG and rubella-IgG (Table 2).
As a control, the anticipated effects of long-term B-
cell depletion on short-lived IgM-secreting plasmablasts
were demonstrated by a persistent decrease in the per-
centage change from baseline total serum IgM and
ACPA-IgM (Figure 4C). No significant differences were
seen in the relative reductions between total IgM (med-
ian 52%, range: 31% to 84%) and ACPA-IgM (median
48%, range: 16% to 85%) (P = 0.27) (Figure 3B). This
was also illustrated by the comparable estimated survival
times of ACPA-IgM-secreting cells, 11.7 years (linear fit
curve, r2 = 0.99), and the total IgM-secreting cell popu-
lation, 12.3 years (r2 = 0.96) (Table 2). Of note, the rela-
tive reduction from baseline of RF-IgM at 24 months
(median 13%, range: 5% to 30%; P = 0.003) was signifi-
cantly more pronounced than other IgM-secreting plas-
mablasts, with an accordingly shorter estimated survival
of RF-IgM-secreting cells of 4.8 years (r2 = 0.96) (Table
2).
With respect to the IgA isotype, the relative reduction
of ACPA-IgA (median 51%, range: 41% to 165%) was
significantly larger than that of total IgA (median 81%,
range: 44% to 92%) (P = 0.02) (Figure 3C). Again
Table 1 Effects of long-term B-cell depletion on serum concentrations of total immunoglobulin secretion,
autoantibodies and protective antibodiesa
Baseline 6 months 12 months 18 months 24 months
Total IgG (g/L) 13.4 (5.4 to 16.5) 10.5 (5.4 to 15.0)b 10.4 (5.2 to 13.6) 9.35 (5.2 to 13.6) 9.15 (5.1 to 12.2)c
ACPA-IgG (U/ml) 423 (65.6 to 1116) 349 (47.0 to 647)b 243 (43.9 to 410) 215 (57.2 to 361) 199 (43.6 to 354)c
Measles-IgG (U/ml) 3.72 (2.43 to 4.71) 3.81 (2.75 to 5.03) 3.84 (2.53 to 5.03) 3.58 (2.63 to 5.04) 3.67 (2.81 to 4.94)
Mumps-IgG (U/ml) 3.16 (0.65 to 4.67) 3.31 (0.53 to 4.77) 3.31 (0.46 to 4.89) 3.33 (0.64 to 4.78) 3.62 (0.67 to 5.11)
Rubella-IgG (U/ml) 101 (50.2 to 303) 100 (29.7 to 310) 91.6 (20.5 to 333) 103 (25.6 to 311) 106 (26.9 to 301)
Total IgM (g/L) 1.7 (0.6 to 3.7) 1.2 (0.3 to 2.1)b 1.1 (0.2 to 2.2) 1.0 (0.2 to 1.9) 0.9 (0.2 to 2.0)c
ACPA-IgM (U/ml) 35.3 (23.4 to 101) 24.4 (16.3 to 72.9)b 21.4 (16.2 to 49.1) 19.8 (14.4 to 37.0) 20.0 (11.8 to 30.8)c
RF-IgM (U/ml) 76.0 (10.0 to 792) 32 (8.0 to 385)b 16 (5 to 555) 13 (2.0 to 310) 10 (1 to 208)c
Total IgA (g/L) 2.0 (1.2 to 5.5) 1.7 (1.0 to 5.7)b 1.8 (0.8 to 5.5) 1.6 (0.8 to 4.3) 1.55 (0.8 to 4.2)c
ACPA-IgA (U/ml) 20.7 (3.16 to 90.8) 12.5 (5.22 to 87.4) 9.79 (2.81 to 97.9) 8.49 (3.69 to 60.3) 8.50 (2.63 to 44.4)c
aACPA = anticitrullinated peptide antibody; Ig = immunoglobulin; RF = rheumatoid factor. Data are medians (ranges). bP < 0.05 (baseline versus 6 months). cP <
0.05 (6 months versus 24 months).
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Figure 3 Comparison of relative effects of long-term B-cell depletion between total immunoglobulin secretion, autoantibody
secretion and protective antibody secretion. Patients were treated with a fixed regimen of 6-monthly anti-CD20 monoclonal antibodies at
baseline, 6, 12 and 18 months with a follow-up of 24 months. (A) Median percentage change from baseline serum concentrations of total
immunoglobulin G (total IgG), rheumatoid arthritis (RA)-specific anticitrullinated protein autoantibodies of the IgG isotype (ACPA-IgG) and IgG-
isotype antibodies against measles (measles-IgG), mumps (mumps-IgG) and rubella (rubella-IgG). (B) Median percentage change from baseline
serum concentrations of total IgM and RA-specific ACPA-IgM. (C) Median percentage change from baseline serum concentrations of total IgA
and RA-specific ACPA-IgA. Brackets in (A) through (C) represent the nonparametric statistical comparison at 24 months between the represented
(auto)antibodies and total IgG/IgA. *P < 0.05. For clear representation, log2 scales are used for the y-axes.
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assuming persistence of B-cell depletion, we estimated
that the survival times were 8.7 years (linear fit curve, r2
= 0.94) for ACPA-IgA-secreting cells and 23.4 years (r2
= 0.96) for the total IgA-secreting cell population (Table
2).
Discussion
Our aim in this study was to investigate how long-term
B-cell depletion affects the humoral immune system in
refractory RA patients. We analysed data from a cohort
of RA patients who received 6-monthly fixed repeat
treatment with rituximab, which led to an extended per-
iod of 2 years of B-cell depletion in blood, bone marrow
and, to a lesser extent, in synovium. We have shown
that plasma cells secreting RA-specific autoantibodies
were significantly more susceptible to this regimen than
plasma cells secreting protective antibodies, thus indicat-
ing that the presence of differentiating CD20+ B cells in
the periphery is necessary to maintain pathogenic auto-
antibody secretion, in contrast to physiological protec-
tive antibody secreting.
In the present study, we investigated RA patients in
whom an extended period of B-cell depletion during a
2-year period was achieved by applying a fixed retreat-
ment protocol with rituximab, an anti-CD20 B-cell-
depleting mAb [8]. Patients in whom prolonged periods
of B-cell depletion in blood were observed after one
treatment course of rituximab have previously been
described; however, in most patients, one treatment
course led to a transient period of 6 to 9 months of B-
cell depletion measured in peripheral blood [7].
Repeated courses of rituximab have been reported pre-
viously; however, in all of those studies, a subsequent
course of rituximab could be given only when B-cell
numbers had returned in peripheral blood [7,19]. Herein
we report on the depletory effects of a fixed repeat
treatment regimen that led to persisting complete B-cell
depletion in blood and bone marrow. Not surprisingly,
B-cell depletion was temporary, as demonstrated by
small increases in B-cell numbers in peripheral blood 6
months after every treatment, at which time patients
received a retreatment course with rituximab. In syno-
vium, depletion of CD79a+ B cells was incomplete. This
can be explained by the fact that CD79a is also
expressed on morphological plasma cells [20,21]. There-
fore, although CD20+ B cells were eliminated in syno-
vium, whether all CD79a+ B cells were eliminated and
only CD79a+ plasma cells persisted remains unclear.
Further confirmation that fixed retreatment led to long-
term B-cell depletion was derived from serum BAFF
concentrations, which significantly increased not only
after the first treatment (as would be expected) but also
after the fixed retreatment regimen. Fixed retreatment
with anti-CD20 mAbs induced long-term B-cell deple-
tion in our RA patients for at least the complete 2 years
of study follow-up.
The treatment protocol of fixed retreatment was set
up on the premise that eliminating autoreactive plasma
cells through long-term B-cell depletion would amelio-
rate refractory disease in RA patients. This hypothesis
was based on previous reports indicating that autoanti-
bodies are produced by long-lived plasma cells as well
as by short-lived plasmablasts [12,13]. The direct and
indirect effects of long-term B-cell depletion on the Ig-
secreting cell population (that is, plasmablasts and
plasma cells) were studied through the serum concen-
trations of IgG, IgM and IgA (auto)antibodies. Flow
cytometry was shown to be less reliable in determining
the depleting effects of this regimen because of its low
specificity (53.6%) for detecting bone marrow plasma
cells and the lack of (auto)antigen specificity. Research-
ers in previous studies who have addressed the effect of
Table 2 Estimated life span of protective and autoreactive humoral immunity during long-term B-cell depletiona
Individual data analysis
Pooled data analysisb Life span in yearsc
Median life span in years (Spearman’s r)d Median (range) Spearman’s r (range)d
Total IgG 38.3 (0.89) 35.5 (10.1 to ∞) 0.75 (0.09 to 0.99)
ACPA-IgG 9.08 (0.89) 10.1 (5.22 to ∞) 0.83 (0.48 to 1.0)
Measles-IgG ∞ (0.66) ∞ (15.9 to ∞) 0.48 (0.01 to 0.92)
Mumps-IgG ∞ (0.90) ∞ (24.0 to ∞) 0.60 (0.04 to 0.84)
Rubella-IgG 75.5 (0.35) 153 (9.03 to ∞) 0.41 (0.04 to 0.93)
Total IgM 12.3 (0.96) 10.6 (6.0 to 36.7) 0.83 (0.38 to 1.0)
ACPA-IgM 11.7 (1.0) 14.9 (5.71 to ∞) 0.88 (0.07 to 0.99)
RF-IgM 4.78 (0.96) 5.27 (4.35 to 7.20) 0.94 (0.68 to 0.99)
Total IgA 33.5 (0.85) 22.8 (8.47 to ∞) 0.77 (0.26 to 0.95)
ACPA-IgA 9.48 (0.71) 9.33 (6.15 to 48.4) 0.88 (0.16 to 0.98)
aACPA = anticitrullinated peptide antibody; Ig = immunoglobulin; RF = rheumatoid factor. bLife span was estimated using the median data for all patients pooled
together as depicted in Figure 3. cLife span was estimated for each individual patient, here summarised in the depicted medians (ranges). dSpearman’s r data are
correlation coefficients of the linear curves used to estimate the life span, which is explained in the Methods section.
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B-cell-depleting therapy on autoantibody concentrations
[14,16,22-26] have reported the effects of a single treat-
ment with rituximab, to which long-lived plasma cells
are known to be resistant. Moreover, repopulation of
autoantibody-producing B-cell clones was not prevented
[27]. In our present study, we have shown that the rela-
tive reduction in ACPA-IgG during long-term B-cell
depletion was more pronounced than that of total IgG
and, on the contrary, that serum concentrations of pro-
tective antibodies against measles, mumps and rubella
remained constant. The latter was not unexpected, as
these protective antiviral antibodies are produced by
long-lived plasma cells that are present throughout life
in humans [28]. Interestingly, within the first 6 months,
we observed an initial decrease of total IgG as well as
ACPA-IgG serum concentrations, reflecting direct elimi-
nation of a small, but relevant, fraction of CD20+ IgG-
producing cells, most likely early plasmablasts. The lat-
ter finding is supported by the concordant decrease in
total IgM-, ACPA-IgM- and RF-IgM-producing plasma-
blasts. Of note, we observed a more rapid decline in RF-
IgM secretion, which warrants further investigation.
Subsequent persisting B-cell depletion resulted in a
significant reduction of ACPA-IgG as compared to total
IgG, even though both are very likely secreted by CD20-
long-lived plasma cells, as evidenced by the complete
depletion of all CD20+ cells (be they B cells or plasma-
blasts) from bone marrow and synovium. Collectively,
these data demonstrate that the effect of long-term B-
cell depletion on humoral autoimmunity in RA is two-
fold: (1) direct elimination of autoreactive B cells,
including ACPA-producing short-lived plasmablasts and
(2) indirect interference in the differentiation of auto-
reactive B-cell towards ACPA-producing long-lived
plasma cells.
Because of the observed indirect effects of continuous
B-cell depletion on (auto)antibody secretion derived
from mature, presumably long-lived plasma cells, we
intended to further illustrate this observation by estimat-
ing the survival of ACPA-IgG secretion, total IgG secre-
tion and protective antibody secretion (that is, measles-
IgG, mumps-IgG and rubella-IgG). Extrapolation of the
presented 2 years of follow-up data regarding antibody
titres was done on the premise of two assumptions: (1)
that B-cell depletion would be continued and the forma-
tion of new plasma cells was negligible and (2) that the
decay of the plasma cell population followed a linear
trend. Therefore, the estimated life span of (auto)anti-
body secretion reflected the senescence and extinction
of established, long-lived plasma cells, which is in accord
with the results of previous studies [28,29]. We esti-
mated that the life span of ACPA-IgG secretion (9.08
years) was significantly shorter than the life span of the
total IgG secretion (38.3 years) and those producing the
protective antibodies against measles, mumps and
rubella (75.5 years to ∞ years). The latter is in line with
data previously reported by Amanna et al. [28], who
demonstrated that B-cell triggering by viral antigens
harbouring a highly repetitive antigenic structure and
inducing cognate CD4+ T-cell help led to differentiation
into plasma cells with an increased life span, guarantee-
ing a lifelong antibody response [30]. Together these
data convincingly illustrate that the autoantibody-secret-
ing plasma cell population is ‘less long-lived’ and likely
more dependent upon replenishment by newly formed B
cells than the classically long-lived plasma cell popula-
tion-producing protective antibodies. How to explain
this different life span between pathogenic autoantibody
secretion and physiological antibody secretion remains
speculative: Either it can be explained by an intrinsic
characteristic of autoreactive plasma cells that is trace-
able to the way autoreactive B cells were triggered [30]
or it can be due to an inflammation-related reduction of
extrinsic factors that support the survival of plasma cells
[31,32], implying that the localisation of autoreactive
plasma cells in synovium is crucial. Another explanation
is that autoreactive plasma cells are more dependent
upon continuous reactivation and differentiation of
autoreactive B-cell [29] or that, in an even more compli-
cated way, a combination of these models plays a role.
The clinical consequences of the observed susceptibil-
ity of autoantibody-producing plasma cells in the pre-
sent study remain speculative. All patients showed
improved disease activity during the study period, and
we were unable to find any correlation between clinical
response and the reduction of ACPA secretion.
Recently, investigators in a large cohort study demon-
strated the superiority of fixed retreatment (to a target
DAS28 score below 2.6) with rituximab every 6 months
compared to an on-demand strategy [33], confirming
our hypothesis of a direct as well as indirect effect of
prolonged B-cell depletion in RA. Therefore, when
assuming that ACPA secretion is essential to the patho-
genesis of RA, targeting autoreactive plasma cells by
means of prolonged B-cell depletion makes sense
biologically.
Conclusion
In our present study, we have demonstrated that the
autoantibody production in refractory RA patients was
more susceptible to the long-term B-cell-depleting
effects of fixed retreatment with anti-CD20 mAbs than
protective antibody production. These results indicate
that the homeostasis and sustainability of pathological
autoantibody secretion is fundamentally different from
physiological protective antibody secretion. Whether
these data are indicative of the existence of a therapeutic
window within which the autoreactive humoral immune
Teng et al. Arthritis Research & Therapy 2012, 14:R57
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response can be targeted without compromising the
physiological long-lived humoral immune system
requires further investigation.
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